Table 1 Patient demographic and baseline disease characteristics
From: A Phase 1b/2 trial of mapatumumab in patients with relapsed/refractory non-Hodgkin's lymphoma
3 mg kg–1 (n =8) | 10 mg kg–1 (n =32) | Total ( n =40) | |
|---|---|---|---|
Sex | |||
Male | 4 (50%) | 20 (63%) | 24 (60%) |
Female | 4 (50%) | 12 (38%) | 16 (40%) |
Race | |||
White | 7 (88%) | 31 (97%) | 38 (95%) |
Black or African American | 1 (13%) | 1 (3%) | 2 (5%) |
Age (years) | |||
Median (range) | 63 (51–74) | 57 (32–81) | 60 (32–81) |
Time from first diagnosis (months) | |||
Median (range) | 36 (5–88) | 40.5 (9–322) | 40 (5–322) |
Number of prior systemic regimens | |||
Median (range) | 3.5 (1–12) | 3.0 (1–9) | 3.0 (1–12) |
Rituximab – combination or single agent (B-cell lymphoma patients) | 8/8 (100%) | 26/28 (93%) | 34/36 (94%) |
ECOG performance status | |||
0 | 3 (38%) | 19 (60%) | 22 (55%) |
1 | 5 (63%) | 11 (34%) | 16 (40%) |
2 | 2 (6%) | 2 (5%) | |
Histological classification at diagnosis | |||
Small lymphocytic | 1 (3%) | 1 (3%) | |
Marginal zone | 1 (3%) | 1 (3%) | |
Follicular | 2 (25%) | 15 (47%) | 17 (43%) |
Grade 1 | 7 (22%) | 7 (18%) | |
Grade 2 | 2 (25%) | 6 (19%) | 8 (20%) |
Grade 3 | 1 (3%) | 1 (3%) | |
Unclassified | 1 (3%) | 1 (3%) | |
Mantle cell | 3 (38%) | 3 (9%) | 6 (15%) |
Diffuse large B cell | 2 (25%) | 7 (22%) | 9 (23%) |
Anaplastic large cell | 1 (3%) | 1 (3%) | |
Peripheral T cell | 3 (9%) | 3 (8%) | |
B cell unclassified | 1 (13%) | 1 (3%) | 2 (5%) |
